<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/Pharma1Dec1125-shutterstock_2709265951-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/Pharma1Dec1125-shutterstock_2709265951-430x241.jpg"/>
                                    
                                    <figcaption>LNK01006 is a next-generation CNS-penetrant. Credit: MY STOCKERS/Shutterstock.com.</figcaption>
                                </figure>
                            </div>
                                             
     
<p>Formation Bio has acquired the global rights, excluding in Greater China, to LNK01006, a highly selective tyrosine kinase 2 (TYK2) inhibitor from Lynk Pharmaceuticals.</p>



<p>This next-generation central nervous system (CNS)-penetrant will be developed by Bleecker Bio, a newly established subsidiary of Formation.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>NPVM: Aptose Biosciences Inc's Tuspetinib </h4></div> </li><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>NPVM: Kymera Therapeutics Inc's KT-413 </h4></div> </li></ul> <div>
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>Lynk Pharmaceuticals will obtain a minority equity stake in Bleecker, along with an upfront payment and potential milestone payments that could reach $605m.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>The deal also includes tiered royalties on any future sales of the asset.</p>



<p>US-based investment fund Pacific Bridge is participating as a minority joint investor in Bleecker.</p>



<p>The asset recently received US Food and Drug Administration (FDA) investigational new drug (IND) clearance, allowing the commencement of first-in-human trials in the US.</p><div> 
                         <div>


            <div>

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div>

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<p>Formation intends to begin a Phase I trial in the first half of 2026, as part of its strategy to expand its portfolio of clinical-stage assets.</p>



<p>LNK01006 offers selective inhibition of TYK2-mediated cytokine signalling and features a pharmacological profile tailored for central immune system modulation.</p><div id="slot-two"></div>



<p>The pharmacologic profile of the therapy may allow for the exploration of indications where central or compartmentalised immune pathways are considered important.</p>



<p>Formation Bio chief business officer David Steinberg stated: “This asset represents a prime example of what we call our ‘Known In New’ strategy of applying validated mechanisms to novel areas of high unmet need.</p>



<p>“Leveraging world class human expertise, robust clinical data sets and homegrown, state-of the-art AI tools, we’ve developed deeply grounded hypotheses around novel therapeutic applications of clinically de-risked asset classes.”</p>



<p>Lynk Pharmaceuticals is a clinical-stage company focused on discovering and developing medicines for immunology and inflammatory diseases.</p>



<p>Lynk Pharmaceuticals CEO Zhao-Kui (ZK) Wan stated: “We are excited to partner with Formation Bio to advance LNK01006 into the clinic.</p>



<p>“Formation’s experienced clinical development team and AI-enabled capabilities provide the ideal environment to translate this compound’s scientific potential into meaningful patient impact.”</p>
<div id="slot-three"></div><p></p>



<div>
    
</div>



                   
               <div>
                 <h2>Pharmaceutical Technology Excellence Awards - Nominations Closed</h2>
                 <p>Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.
<br/>
<br/>
<strong>Excellence in Action</strong>
<br/>Imagene’s Oncology Intelligence (OI) Suite  has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.</p>
Discover the Impact

             </div>

<p>Formation Bio has acquired global rights, excluding Greater China, to Lynk Pharma's TYK2 inhibitor, LNK01006. This CNS-penetrant drug will be developed by Formation's subsidiary, Bleecker Bio. Lynk will receive a minority stake in Bleecker, upfront and milestone payments up to $605m, and tiered royalties. The drug has FDA IND clearance for trials in the US. Formation plans a Phase I trial in 2026, aiming to expand its clinical-stage portfolio. Lynk focuses on immunology and inflammatory diseases.</p>

Formation Bio gains global rights to Lynk Pharma’s TYK2 inhibitor